Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
201 hedge funds and large institutions have $1.92B invested in Portola Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 56 reducing their positions, and 36 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 56
4% less funds holding
Funds holding: 209 → 201 (-8)
17% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 36
20% less capital invested
Capital invested by funds: $2.41B → $1.92B (-$489M)
23% less call options, than puts
Call options by funds: $22.2M | Put options by funds: $28.9M
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$26.4M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$21.4M |
| 3 |
Two Sigma Investments
New York
|
+$16.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.2M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$90.8M |
| 2 |
JP Morgan Chase
New York
|
-$17.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$8.35M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$5.33M |
PTLA Hedge Fund Activity: Q2 2019 in Review
201 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2019, worth a combined $1.92B — down 20% from $2.41B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of PTLA and 30 opened new positions — a net loss of 6 holders — while 56 trimmed existing stakes and 71 added.
The largest buyer was William Blair Investment Management, adding an estimated $26.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $90.8M sold.
- 201 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2019, down from 209 in Q1 2019.
- Funds reported $1.92B of Portola Pharmaceuticals, Inc. stock for Q2 2019, down 20% quarter-over-quarter.
- 30 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2019 and 36 closed out, a net change of -6 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q2 2019 was William Blair Investment Management, an estimated $26.4M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q2 2019 was Deerfield Management, an estimated $90.8M sold.
Based on aggregated 13F filings for Q2 2019.